躯体症状障碍的精神药物治疗。

Bettahalasoor Somashekar, Ashok Jainer, Balaji Wuntakal
{"title":"躯体症状障碍的精神药物治疗。","authors":"Bettahalasoor Somashekar,&nbsp;Ashok Jainer,&nbsp;Balaji Wuntakal","doi":"10.3109/09540261.2012.729758","DOIUrl":null,"url":null,"abstract":"<p><p>Somatic symptoms are often common causes for medical consultation. The treatment of somatic symptoms disorders is complicated by lack of boundary, conceptual clarity, and overemphasis on psychosocial causation and effectiveness of psychological treatments. In clinical practice all classes of psychotropics are used to treat somatic symptoms disorder. Five principal groups of drugs such as tricyclic antidepressants (TCA), serotonin reuptake inhibitors (SSRI), serotonin and noradrenalin reuptake inhibitors (SNRI), atypical antipsychotics and herbal medication are systematically studied. The evidence indicates that all five groups are effective in a wide range of disorders. All classes of antidepressants seem to be effective against somatoform and related disorders. SSRIs are more effective against hypochondriasis and body dysmorphic disorder (BDD), and SNRIs appear to be more effective than other antidepressants when pain is the predominant symptom. Research leaves many unanswered questions regarding dosing, duration of treatment, sustainability of improvement in the long term and differential response to different class drugs. Further studies need to focus on treatments based on clinical features/psychopathology and collaborative research with other specialists in understanding the relation of somatic symptom disorders and functional somatic syndromes (FSS), and comparing psychotropics and non-psychotropics and combinations treatments.</p>","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"107-15"},"PeriodicalIF":0.0000,"publicationDate":"2013-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2012.729758","citationCount":"40","resultStr":"{\"title\":\"Psychopharmacotherapy of somatic symptoms disorders.\",\"authors\":\"Bettahalasoor Somashekar,&nbsp;Ashok Jainer,&nbsp;Balaji Wuntakal\",\"doi\":\"10.3109/09540261.2012.729758\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Somatic symptoms are often common causes for medical consultation. The treatment of somatic symptoms disorders is complicated by lack of boundary, conceptual clarity, and overemphasis on psychosocial causation and effectiveness of psychological treatments. In clinical practice all classes of psychotropics are used to treat somatic symptoms disorder. Five principal groups of drugs such as tricyclic antidepressants (TCA), serotonin reuptake inhibitors (SSRI), serotonin and noradrenalin reuptake inhibitors (SNRI), atypical antipsychotics and herbal medication are systematically studied. The evidence indicates that all five groups are effective in a wide range of disorders. All classes of antidepressants seem to be effective against somatoform and related disorders. SSRIs are more effective against hypochondriasis and body dysmorphic disorder (BDD), and SNRIs appear to be more effective than other antidepressants when pain is the predominant symptom. Research leaves many unanswered questions regarding dosing, duration of treatment, sustainability of improvement in the long term and differential response to different class drugs. Further studies need to focus on treatments based on clinical features/psychopathology and collaborative research with other specialists in understanding the relation of somatic symptom disorders and functional somatic syndromes (FSS), and comparing psychotropics and non-psychotropics and combinations treatments.</p>\",\"PeriodicalId\":306151,\"journal\":{\"name\":\"International Review of Psychiatry (Abingdon, England)\",\"volume\":\" \",\"pages\":\"107-15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3109/09540261.2012.729758\",\"citationCount\":\"40\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Review of Psychiatry (Abingdon, England)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3109/09540261.2012.729758\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Review of Psychiatry (Abingdon, England)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3109/09540261.2012.729758","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 40

摘要

躯体症状通常是求医问诊的常见原因。躯体症状障碍的治疗由于缺乏边界、概念清晰、过度强调心理社会因果关系和心理治疗的有效性而变得复杂。在临床实践中,所有种类的精神药物都用于治疗躯体症状障碍。系统研究了三环类抗抑郁药(TCA)、血清素再摄取抑制剂(SSRI)、血清素和去甲肾上腺素再摄取抑制剂(SNRI)、非典型抗精神病药和草药等五大类药物。证据表明,这五组药物对多种疾病都有效。所有种类的抗抑郁药似乎对躯体形式和相关疾病都有效。SSRIs对疑病症和身体畸形障碍(BDD)更有效,当疼痛是主要症状时,SNRIs似乎比其他抗抑郁药更有效。研究留下了许多悬而未决的问题,如剂量、治疗持续时间、长期改善的可持续性以及对不同类别药物的不同反应。进一步的研究需要集中在基于临床特征/精神病理学的治疗上,并与其他专家合作研究躯体症状障碍与功能性躯体综合征(FSS)的关系,比较精神药物和非精神药物以及联合治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Psychopharmacotherapy of somatic symptoms disorders.

Somatic symptoms are often common causes for medical consultation. The treatment of somatic symptoms disorders is complicated by lack of boundary, conceptual clarity, and overemphasis on psychosocial causation and effectiveness of psychological treatments. In clinical practice all classes of psychotropics are used to treat somatic symptoms disorder. Five principal groups of drugs such as tricyclic antidepressants (TCA), serotonin reuptake inhibitors (SSRI), serotonin and noradrenalin reuptake inhibitors (SNRI), atypical antipsychotics and herbal medication are systematically studied. The evidence indicates that all five groups are effective in a wide range of disorders. All classes of antidepressants seem to be effective against somatoform and related disorders. SSRIs are more effective against hypochondriasis and body dysmorphic disorder (BDD), and SNRIs appear to be more effective than other antidepressants when pain is the predominant symptom. Research leaves many unanswered questions regarding dosing, duration of treatment, sustainability of improvement in the long term and differential response to different class drugs. Further studies need to focus on treatments based on clinical features/psychopathology and collaborative research with other specialists in understanding the relation of somatic symptom disorders and functional somatic syndromes (FSS), and comparing psychotropics and non-psychotropics and combinations treatments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信